Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
View Session ViewAttendees 36

Adult ID

Epidemiology & Infection Control

Pediatric ID

Trainee

Transplant
Symposium

115 - Using Novel Antimicrobial Therapies in Transplant ID: Preserving the Pipeline

Friday, October 1, 2021
4:15 PM - 5:30 PM EDT

    Moderator(s)

  • Steven Pergam, MD, MPH

    Associate Professor
    Fred Hutchinson Cancer Research Center; University of Washington
    Seattle, WA, United States

    Chimerix (Individual(s) Involved: Self): Clinical Trial; Global Life Technologies, Inc (Individual(s) Involved: Self): Research Grant or Support; Merck & Co. (Individual(s) Involved: Self): Scientific Research Study Investigator; Sanofi Aventis (Individual(s) Involved: Self): Other Financial or Material Support, Provided vaccines for clinical trial sponsored by the NIH

  • Samuel Aitken, PharmD, MPH, BCIDP

    Clinical Pharmacist Specialist - Infectious Diseases
    Michigan Medicine
    Ann Arbor, TX, United States

    Melinta Therapeutoics (Individual(s) Involved: Self): Consultant, Grant/Research Support

    • Speaker(s)

  • Erin McCreary, PharmD, BCPS, BCIDP

    Clinical Assistant Professor, Director of Infectious Diseases Improvement and Clinical Research Innovation
    University of Pittsburgh, UPMC
    Pittsburgh, PA, United States

    AbbVie (Individual(s) Involved: Self): Consultant; Cidara (Individual(s) Involved: Self): Consultant; Entasis (Individual(s) Involved: Self): Consultant; Ferring (Individual(s) Involved: Self): Consultant; Infectious Disease Connect, Inc (Individual(s) Involved: Self): Director of Stewardship Innovation, Other Financial or Material Support; Merck (Individual(s) Involved: Self): Consultant; Shionogi (Individual(s) Involved: Self): Consultant; Summit (Individual(s) Involved: Self): Consultant

  • Sarah Spitznogle, PharmD

    Transplant Infectious Diseases Pharmacist
    Pharmacy
    UT Southwestern
    Coppell, TX, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • Kenneth Olivier, MD, MPH

    Chief, Pulmonary Branch, Laboratory of Chronic Airway Infection
    National Heart, Lung, and Blood Institute, National Institutes of Health
    Bethesda, MD, United States

    Beyond Air (Individual(s) Involved: Self): Research Grant or Support

Participants should be aware of the following financial/non-financial relationships:
Steven A. Pergam, MD, MPH: Chimerix (Individual(s) Involved: Self): Clinical Trial; Global Life Technologies, Inc (Individual(s) Involved: Self): Research Grant or Support; Merck & Co. (Individual(s) Involved: Self): Scientific Research Study Investigator; Sanofi Aventis (Individual(s) Involved: Self): Other Financial or Material Support, Provided vaccines for clinical trial sponsored by the NIH
Samuel L. Aitken, PharmD, MPH, BCIDP: Melinta Therapeutoics (Individual(s) Involved: Self): Consultant, Grant/Research Support
Erin K. McCreary, PharmD, BCPS, BCIDP: AbbVie (Individual(s) Involved: Self): Consultant; Cidara (Individual(s) Involved: Self): Consultant; Entasis (Individual(s) Involved: Self): Consultant; Ferring (Individual(s) Involved: Self): Consultant; Infectious Disease Connect, Inc (Individual(s) Involved: Self): Director of Stewardship Innovation, Other Financial or Material Support; Merck (Individual(s) Involved: Self): Consultant; Shionogi (Individual(s) Involved: Self): Consultant; Summit (Individual(s) Involved: Self): Consultant
Sarah L. Spitznogle, PharmD: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Kenneth N. Olivier, MD, MPH: Beyond Air (Individual(s) Involved: Self): Research Grant or Support

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
ACPE Credits: ACPE 1.25 Knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-21-001-H01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • identify current evidence supporting use of each antimicrobial agent in specific clinical indication(s)
  • discuss role of susceptibility testing (correlation with outcomes etc.)
  • discuss role of therapeutic drug monitoring (if relevant)

Presentations:

  • Rolling out New GNR Agents in Transplant: Case Use with Cefiderocol

    Speaker: Erin K. McCreary, PharmD, BCPS, BCIDP – University of Pittsburgh, UPMC

  • Suba-itraconazole or Isavuconazole for Prophylaxis and Treatment of Invasive Fungal Infections: Ready for Prime Time?

    Speaker: Sarah L. Spitznogle, PharmD – UT Southwestern

  • Treating Pulmonary Mycobacterium Abscessus Infections: Beyond the Guidelines

    Speaker: Kenneth N. Olivier, MD, MPH – National Heart, Lung, and Blood Institute, National Institutes of Health